Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma : Clinical outcomes in 245 subjects in a Japanese multiinstitutional study (pages 1623–1631)
Hiroshi Onishi, Tsutomu Araki, Hiroki Shirato, Yasushi Nagata, Masahiro Hiraoka, Kotaro Gomi, Takashi Yamashita, Yuzuru Niibe, Katsuyuki Karasawa, Kazushige Hayakawa, Yoshihiro Takai, Tomoki Kimura, Yutaka Hirokawa, Atsuya Takeda, Atsushi Ouchi, Masato Hareyama, Masaki Kokubo, Ryusuke Hara, Jun Itami and Kazunari Yamada
Article first published online: 18 AUG 2004 | DOI: 10.1002/cncr.20539
Patients (n = 245) with Stage I nonsmall cell lung carcinoma (T1N0M0, n=155; T2N0M0, n=90) were treated with hypofractionated high-dose stereotactic irradiation in 13 institutions. Local control and survival rates in selected patients (medically operable, biologic effective dose ≥ 100 gray) were excellent, and were potentially equivalent to those of surgery.